Moderna and Merck’s experimental cancer vaccine, when used in combination with Merck’s blockbuster therapy Keytruda, reduced the risk of death or relapse in patients with the most deadly form of skin cancer by half after roughly three years, according to midstage trial data released Thursday.
Clinical Trials
MD Anderson at Cooper first in world to enroll patient in promising trial for metastatic melanoma
Researchers at MD Anderson Cancer Center at Cooper are leading the way in new approaches to treating advanced melanoma using tumor infiltrating lymphocyte therapy.
Efficacy Shown for New Melanoma Therapeutic Vaccine
FRIDAY, Dec. 15, 2023 (HealthDay News) — In a recent trial, a new melanoma vaccine, mRNA-4157 (V940), when taken in combination with Keytruda (pembrolizumab), was found to be effective in battling the deadly skin cancer.
OBX-115 Elicits Responses in Advanced or Metastatic Melanoma
The tumor-infiltrating lymphocyte (TIL) cell therapy OBX-115 produced responses with no dose-limiting toxicities (DLTs) in heavily pretreated patients with advanced or metastatic melanoma whose who had progressed on anti–PD-1 and anti–CTLA-4 therapy with disease that was primary-resistant to immune checkpoint inhibitor (ICI) therapy, according to topline data from a phase 1 trial (NCT05470283).